Evidence map›Paper›PMID 30789928›Full record

ArticlePloS one2019

Epidemiological and clinical features of invasive pneumococcal disease caused by serotype 12F in adults, Japan.

Reiko Shimbashi, Bin Chang, Yoshinari Tanabe, Hiroaki Takeda, Hiroshi Watanabe, Tetsuya Kubota, Kei Kasahara, Kengo Oshima, Junichiro Nishi, Takaya Maruyama and 14 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Sex Hormones and Lung Inflammation.Advances in experimental medicine and biology · 2021
    Article
  6. Distribution and Variation of Serotypes and Pneumococcal Surface Protein A Clades ofFrontiers in cellular and infection microbiology · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 2 countries.

Reiko ShimbashiField Epidemiology Training Program, National Institute of Infectious Diseases, Tokyo, Japan.
Bin ChangDepartment of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Yoshinari TanabeDepartment of Respiratory Medicine, Niigata Prefectural Shibata Hospital, Shibata, Japan.
Hiroaki TakedaDepartment of Respiratory Medicine, Yamagata Saisei Hospital, Yamagata, Japan.
Hiroshi WatanabeDepartment of Infection Control and Prevention, Kurume University School of Medicine, Kurume, Japan.
Tetsuya KubotaDepartment of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
Kei KasaharaCenter for Infectious Diseases, Nara Medical University, Nara, Kashihara, Japan.
Kengo OshimaDepartment of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, Miyagi, Sendai, Japan.
Junichiro NishiDepartment of Microbiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Takaya MaruyamaDepartment of Medicine, National Hospital Organization, Mie Hospital, Tsu, Japan.
Koji KuronumaDepartment of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Jiro FujitaDepartment of Infectious, Respiratory and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Tatsuki IkuseDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.ORCID 0000-0002-0417-6797
Yuki KinjoDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Department of Bacteriology, Tokyo, Japan.
Motoi SuzukiDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Anusak KerdsinFaculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Tomoe ShimadaInfectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Munehisa FukusumiInfectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Keiko Tanaka-TayaInfectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Tamano MatsuiInfectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Tomimasa SunagawaInfectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Makoto OhnishiDepartment of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Kazunori OishiInfectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-8637-0509
Adult IPD Study Group
National Institute of Infectious Diseases · JPTohoku University · JPJikei University School of Medicine · JPKagoshima University · JPKasetsart University · THKōchi University · JPKurume University · JPNagasaki University · JPNara Medical University · JPNational Mie Hospital · JPNiigata Prefectural Shibata Hospital · JPNiigata University · JPSapporo Medical University · JPUniversity of the Ryukyus · JPYamagata City Hospital Saiseikan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhanced surveillance of invasive pneumococcal disease (IPD) in adults was conducted during April 2013-March 2018 in 10 of 47 prefectures in Japan, and a total of 1277 IPD patients were enrolled. An emergence of IPD caused by serotype 12F was identified during May 2015-March 2018 through this surveillance. 12F isolates were composed of four related sequence types. In total, 120 patients with 12F IPD were reported during this period. To characterize the clinical features of 12F IPD, the disease characteristics of these patients were compared with those of 1157 patients with non-12F IPD. Compared with the non-12F IPD patients, a significantly lower proportion of 12F IPD patients was aged 65 years or older (55% vs. 70%), vaccinated with 23-valent pneumococcal polysaccharide (4% vs. 14%), had comorbid illness (65% vs. 77%), or were immunocompromised (19% vs. 30%; all P < 0.05). No significant difference in the proportion of case fatalities was found between the two groups. The proportions of those aged 65 years or older (53% vs. 69%) and with bacteremic pneumonia (35% vs. 69%) were significantly lower in 17 patients who died from 12F IPD than in 205 patients who died from non-12F IPD (all P < 0.05). Differences in clinical features were similarly found between 12F IPD patients and patients in low- or intermediate-level invasive potential serogroups. Our data demonstrated that serotype 12F was associated with IPD in younger adults and a lower proportion of comorbid illness, including immunocompromised conditions, in adult IPD, suggesting the high invasive potential of the serotype 12F. In addition, patients who died from 12F IPD were younger and had proportionately more bacteremia without focus. These findings may provide new insight into the pathogenesis of IPD in adults caused by 12F serotype with a high invasive potential.

Indexed as

AdolescentAdultAgedAged, 80 and overComorbidityEpidemiological MonitoringFemaleHumansJapanMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeYoung Adult13-valent pneumococcal vaccine23-valent pneumococcal capsular polysaccharide vaccinePneumococcal Vaccines

Identifiers

PMID30789928
PMCPMC6383924
OpenAlexW2917603959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.